Page 374 - Read Online

Sommariva Liver metastases and HIPEC

peritoneal and liver metastases arise from different REFERENCES
ways of diffusion (loco-regional vs. haematogenous),
probably reflecting a different cancer cell genetics or 1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J,
epigenetic alterations; as previously hypothesized, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL,
a curative surgical resection for cancer is only François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-
cytoreductive surgery: surgery removes all detectable gynecologic malignancies: results of the EVOCAPE 1 multicentric
disease, but does not completely eradicate all tumor 2. prospective study. Cancer 2000;88:358-63.
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis
cells, since micro-metastases and circulating tumor from colorectal cancer. Br J Surg 2002;89:1545-50.
cells are present in the blood of colorectal cancer 3. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal
patients after radical primary tumor resection in one carcinomatosis in nongynecologic malignancy. A prospective study of
third of all patients [36] . The fact that survival after prognostic factors. Cancer 1989;63:364-7.
HIPEC is not lowered by concomitant liver resection 4. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and
disease-progression benefits with treatment regimens for advanced
adds an important piece of evidence supporting colorectal cancer: a meta-analysis. Lancet Oncol 2007;8:898-911.
this hypothesis that needs to be confirmed by more 5. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J,
evidence. Germer CT, Kerscher AG, Pelz JO. Influence of modern systemic
therapies as adjunct to cytoreduction and perioperative intraperitoneal
chemotherapy for patients with colorectal peritoneal carcinomatosis:
CONCLUSION a multicenter study. Ann Surg Oncol 2011;18:1560-7.
6. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe
The reported data confirmed that CS-HIPEC allows JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete
cytoreductive surgery plus intraperitoneal chemohyperthermia with
the achievement of long-term survival in patients oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin
usually referred for palliative systemic treatment. Oncol 2009;27:681-5.
Although an advantage of HIPEC in terms of 7. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current
oncological outcome over systemic treatments therapeutic options for peritoneal metastases from colorectal cancer. J
has been not yet clearly proven, patients with no Surg Oncol 2012;107:566-73.
macroscopic residual disease, low peritoneal tumor 8. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier
P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck
load and few liver metastases seem to be the D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem
best indicated for CS + HIPEC + LR. CS + HIPEC E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract
associated with LR have mortality and morbidity Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen
rates similar to that observed with CS + HIPEC und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie
alone, although major hepatectomy has rarely been (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG);
performed. For these reasons patients with peritoneal Fédération Francophone de Cancérologie Digestive (FFCD).
Perioperative chemotherapy with FOLFOX4 and surgery versus
carcinomatosis and liver metastases from colorectal surgery alone for resectable liver metastases from colorectal cancer
cancer should be referred to a tertiary center for (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet
selection of the more appropriate treatment, possibly 2008;371:1007-16.
within clinical trials. 9. Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos
T, Göhl J, Hohenberger W. Surgical management of pulmonary
metastases from colorectal cancer in 153 patients. Ann Surg Oncol
DECLARATIONS 2006;13:1538-44.
10. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal
Authors’ contributions and 130 appendiceal cancer patients with peritoneal carcinomatosis
treated by cytoreductive surgery and intraperitoneal chemotherapy.
A. Sommariva contributed solely to the paper. Ann Surg 1995;221:124-32.
11. Carpizo DR, D’Angelica M. Liver resection for metastatic colorectal
Financial support and sponsorship cancer in the presence of extrahepatic disease. Ann Surg Oncol
None. 2009;16:2411-21.
12. Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, Pignon
Conflicts of interest JP, Ducreux M. Results of R0 resection for colorectal liver metastases
associated with extrahepatic disease. Ann Surg Oncol 2004;11:274-
There are no conflicts of interest. 80.
13. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V,
Patient consent Malka D, Pignon JP, Lasser P. Hepatic and extrahepatic colorectal
The patient of the computed tomography scan of metastases: when resectable, their localization does not matter,
Figure 1 gave his consent for publication. but their total number has a prognostic effect. Ann Surg Oncol
2005;12:900-9.
14. Aoki T, Umekita N, Tanaka S, Noda K, Warabi M, Kitamura M.
Ethic approval Prognostic value of concomitant resection of extrahepatic disease
Not applicable. in patients with liver metastases of colorectal origin. Surgery

366 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 21, 2017